Monooxygenase DBH-like 1 (MOXD1)

Monooxygenase DBH-like 1 (MOXD1) is a membrane-bound, copper-dependent, ascorbate-requiring enzyme belonging to the type II monooxygenase family. It shares key structural features with dopamine beta-monooxygenase and related enzymes involved in monoamine metabolism, though its preferred natural substrate is unclear. MOXD1 localizes to the endoplasmic reticulum and is tightly membrane-associated, participating in hydroxylation reactions of hydrophobic substrates and post-translational modifications such as glycosylation. In normal physiology, it is linked to neurotransmitter biosynthesis and neural crest development. In cancer biology, elevated MOXD1 expression promotes glioblastoma cell proliferation and migration, while its reduced expression functions as a "tumor suppressor" in neuroblastoma. MOXD1 knockdown induces apoptosis through ER-mitochondrial stress pathways and disrupts cell cycle progression. These findings highlight MOXD1 as a candidate therapeutic target in oncology and a potential biomarker for cancer progression and prognosis[1][2][3][4][5].

Other names

DBH-like monooxygenase protein 1monooxygenase XMOXPRO5780DJ248E1.1UNQ2493/PRO5780dJ248E1.1dopamine-oxygenaseDBH-related proteinMNCb-52033230402N08Rik

No specific agents documented; in glioblastoma, MOXD1 modulates ER stress and apoptosis, glycosylation pathways, and cancer cell viability and migration—thus, hypothetical agents could inhibit these cancer-related functions[4]